News archive
Showing 772 results
January 2021
-
Media Release
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic idiopathic urticaria (CIU)
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic idiopathic urticaria (CIU) in patients with an inadequate response to H1 anthistamines1 Currently… -
Statement
Novartis US response to COVID-19
December 2020
-
Story Hope
Working Together at Novartis to Fight COVID-19 and Help People in Need
Novartis is fighting COVID-19 broadly, from committing R&D resources to better understand and treat the disease to reaching out to individuals and communities in need.
-
Media Release
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
-
Media Release
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval… -
Media Release
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
-
Media Release
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1 Kisqali plus endocrine therapy had a median OS of nearly five years (58.7… -
Media Release
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
-
Media Release
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase… -
Media Release
Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine
-
Media Release
Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine
The Know Migraine Mission initiative seeks to challenge misconceptions and start new conversations about migraine Karamo Brown to connect directly with people affected by migraine to share…